Moonlake Immunotherapeutics (MLTX) PT Raised to $58 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts MLTX Hot Sheet
Price: $11.78 -6.28%
Rating Summary:
12 Buy, 4 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
12 Buy, 4 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Jefferies analyst Kelly Shi raised the price target on Moonlake Immunotherapeutics (NASDAQ: MLTX) to $58.00 (from $30.00) while maintaining a Buy rating.
You May Also Be Interested In
- JPMorgan Downgrades Banco del Bajio SA (BBAJIOO:MM) (BBAJF) to Neutral
- Pluxee France SA (PLX:FP) PT Lowered to EUR12.50 at Morgan Stanley
- Natwest Group PLC (NWG:LN) (NWG) PT Lowered to GBP7.80 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
